Neurocrine Buys Rare Disease Company for $2.9 Billion

Breakthrough Deal for Rare Disorder Treatment

Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion , marking one of the year's largest biotech deals. The acquisition centers around Vykat, the only approved treatment for hyperphagia in Prader-Willi patients , a rare genetic disorder that causes insatiable hunger and can lead to life-threatening obesity.

The all-cash deal values Soleno at $53 a share, a 34% premium to its closing price on Thursday . This purchase price represents a 51% premium to Soleno's volume-weighted average trading price over the last 30 days , sending Soleno shares soaring over 30% in pre-market trading.

Vykat XR addresses hyperphagia in Prader-Willi syndrome, a rare chromosome 15 gene-expression disorder affecting ~10,000 U.S. patients and driving severe metabolic, behavioral, and mortality risks . In an investor presentation, Neurocrine notes that Prader-Willi patients have a shorter life expectancy and about half of the deaths are in those age 18 or younger .

Remarkable Commercial Success Story

Soleno's drug, Vykat, was approved in March 2025 to treat hyperphagia in patients with the rare genetic disease . Since its launch, the medication has demonstrated exceptional market adoption that caught industry attention.

Since its FDA approval and successful U.S. launch in the second quarter of 2025, VYKAT XR has demonstrated strong early adoption, generating $190 million in 2025 revenue, including $92 million for Soleno in the fourth quarter alone . This rapid uptake reflects the urgent medical need in a patient population that previously had no approved treatment options.

BMO Capital Markets forecasted $450 million in sales this year for Vykat XR, hitting over $2 billion worldwide by the mid-2030s , positioning it as a potential blockbuster drug. However, "Acceleration of the commercial launch and penetration will be critical for Neurocrine to drive ROI of the asset and acquisition," the analysts wrote .

Strategic Portfolio Expansion

For Neurocrine, the acquisition represents a significant expansion beyond its traditional focus areas. Once the deal closes, Vykat XR will become Neurocrine's third commercial product. Its first drug on the market is Ingrezza, which was approved in 2017 as the first treatment for tardive dyskinesia. Crenessity followed seven years later, in December 2024, as the first new drug in seven decades for classic congenital adrenal hyperplasia .

Post-transaction, Neurocrine will hold three marketed first-in-class franchises—Ingrezza ($2.51B, 2025), Crenessity ($301M, 2025), and Vykat XR—strengthening rare disease/endocrinology diversification . The deal aligns with industry trends, as large-cap pharmaceutical companies face a "patent cliff" between 2026 and 2030—where hundreds of billions in revenue are at risk from generic competition—they are increasingly willing to pay high premiums for companies that have already secured FDA approval and demonstrated early commercial traction .

Future Growth Potential

Pending customary conditions, Neurocrine and Soleno expect to close the transaction within 90 days. The boards of both companies have signed off on the deal . Patent coverage for Vykat XR is expected into the mid-2040s, extending exclusivity runway and supporting longer-duration revenue growth as Neurocrine scales access and commercialization .

The acquisition positions Neurocrine to leverage its established commercial infrastructure to expand patient access. Vykat is currently under European Medicines Agency review, but Gano said Neurocrine has no plans to commercialize Vykat in Europe at this time. The deal value and financial models for the drug are based only on the U.S. market, and Gano said the company plans to focus on the U.S. opportunity .

This deal exemplifies how biotech companies are increasingly targeting rare diseases with significant unmet medical needs. With Vykat's proven commercial success and strong intellectual property protection, Neurocrine has positioned itself to capture substantial value while addressing a critical healthcare gap for thousands of patients and families affected by Prader-Willi syndrome.